Obesity最新文献

{"title":"The Obesity Society 2025 Awards and Grants","authors":"","doi":"10.1002/oby.70220","DOIUrl":"https://doi.org/10.1002/oby.70220","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"153-158"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148215165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Excess Weight Gain Among Adolescent Military-Dependents at High Risk for Obesity","authors":"Lisa M. Ranzenhofer,&nbsp;Lisa M. Shank,&nbsp;Katherine Thompson,&nbsp;Natasha Schvey,&nbsp;Denise E. Wilfley,&nbsp;Jami F. Young,&nbsp;Natasha L. Burke,&nbsp;Cara H. Olsen,&nbsp;Jason M. Lavender,&nbsp;Ruby Schrag,&nbsp;Sarah Jorgensen,&nbsp;Jeffrey Quinlan,&nbsp;David A. Klein,&nbsp;Mark Haigney,&nbsp;Jack A. Yanovski,&nbsp;Tracy Sbrocco,&nbsp;Marian Tanofsky-Kraff","doi":"10.1002/oby.70165","DOIUrl":"10.1002/oby.70165","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Given their unique psychosocial milieu, military-dependent youth (children of service members) may be vulnerable to excess weight gain, adverse cardiometabolic health, and binge eating. This study aimed to test the effects of group interpersonal psychotherapy (IPT), relative to a standard-of-care health education (HE) group, on these outcomes in adolescent military-dependents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Military-dependent 12 to 17-year-olds with BMI ≥ 85th percentile and elevated anxiety and/or recent loss-of-control-eating participated in a multisite cluster randomized controlled trial comparing 12 weeks of adapted group IPT, targeting psychosocial problems, to a HE group. BMI, cardiometabolic health, and binge eating were assessed at baseline, posttreatment, and 1-year follow-up. BMI and cardiometabolic variables were measured or retrieved from electronic medical records at 2- and 3-year follow-ups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We were not able to recruit a fully powered trial; however, we analyzed data from 153 adolescent military-dependents (43.8% boys) with LOC-eating and/or high anxiety. There were no group differences between IPT and HE on outcomes. Some improvements in BMI indices, glucose regulation, and binge eating (<i>p</i> &lt; 0.001) were observed across both groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Group-based interventions may positively impact weight trajectories and cardiometabolic health among adolescent military-dependents. Future studies should elucidate potential moderators and mechanisms of interventions on outcomes in this important population.</p>\u0000 \u0000 <p>\u0000 <b>Trial Registration:</b> ClinicalTrials.gov identifier NCT02671292.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"54-64"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Vertical Sleeve Gastrectomy in Youth-Onset Type 2 Diabetes: Changes in Glycemia, Insulin Sensitivity, and Secretion","authors":"Tyler J. Dobbs,&nbsp;Laura Pyle,&nbsp;Jaime M. Moore,&nbsp;Justin Garrish,&nbsp;Cecilia Diniz Behn,&nbsp;Dylan Weissenkampen,&nbsp;Amy D. Baumgartner,&nbsp;Susan Gross,&nbsp;Grant Schutte,&nbsp;Carissa Birznieks,&nbsp;Isabella Melena,&nbsp;Lauryn Remmers,&nbsp;Lynette Driscoll,&nbsp;Melanie G. Cree,&nbsp;Megan M. Kelsey,&nbsp;Amy S. Shah,&nbsp;Thomas H. Inge,&nbsp;Petter Bjornstad,&nbsp;Kristen J. Nadeau","doi":"10.1002/oby.70140","DOIUrl":"10.1002/oby.70140","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study evaluated impacts of vertical sleeve gastrectomy (VSG) on glycemic and cardiometabolic outcomes in youth-onset type 2 diabetes (YO-T2D).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pre- and postoperative (3 and 12 months) anthropometrics, mixed-meal tolerance test (MMTT) and body composition assessments, and hyperglycemic clamps (preoperative and 12 months postoperatively) were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Weight (−24.6 ± 5.2 kg at 3 months; −31.0 ± 5.2 kg at 12 months) and BMI (−8.5 ± 2.0 kg/m²; −10.8 kg/m²) fell by 18% and 23%, respectively (all <i>p</i> &lt; 0.01). Body fat decreased 6.4% (<i>p</i> = 0.01) at 12 months, and fat mass by 16.8 ± 4.7 kg (<i>p</i> = 0.01). MMTT-stimulated GLP-1, PYY, insulin, and C-peptide secretion increased and insulin clearance, glucose, HbA1c (6.6% ± 0.2% to 5.7% ± 0.2%, <i>p</i> = 0.003), free fatty acids (FFA), LDL, triglycerides, adipose-focused Adipo-IR, liver transaminases and hepatic-predominant insulin sensitivity (Si) (HOMA-IR) decreased at 3 months post VSG. With maximal 12-month weight loss, MMTT-stimulated insulin, C-peptide, and GLP-1 responses attenuated, insulin clearance increased, muscle-predominant Si (hyperglycemic clamp M/I, Matsuda index, static/dynamic oral minimal modeling), β-cell function, resting heart rate, systolic blood pressure, and HDL improved, and all 3-month improvements persisted, with 86% of participants off diabetes medications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>VSG in YO-T2D produces rapid and sustained improvements in weight, body composition, cardiometabolic health, Si, FFA, β-cell function, and glycemia, with most no longer needing diabetes medications.</p>\u0000 \u0000 <p>\u0000 <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT03620773.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"121-133"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146222628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study","authors":"Leslie J. Heinberg,&nbsp;Alexandra M. Lee,&nbsp;Gary D. Foster,&nbsp;Amy DiVita,&nbsp;Matthew Allman,&nbsp;Daniel Rotroff,&nbsp;Carla Bou Dargham,&nbsp;Michelle I. Cardel","doi":"10.1002/oby.70056","DOIUrl":"10.1002/oby.70056","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Limited data exist on telemedicine prescribing of semaglutide and tirzepatide. The effects of a telehealth obesity management program combining the provision of semaglutide and tirzepatide with a behavioral program tailored for long-acting antiobesity medications (AOMs) were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this single-arm study, 180 participants recruited from a telehealth medical obesity program received a virtual behavioral program tailored for long-acting AOMs, Bluetooth wireless scales, and a blood pressure (BP) cuff. Participants' (mean age = 44.1; 91% female; 81% White; mean weight = 102.8 kg) weight, BP, eating habits, dietary quality, physical activity, and side effects were assessed at baseline and at 12 and 24 weeks. Wilcoxon rank sum tests were conducted, and <i>p</i> values were adjusted using a false discovery rate approach. Intent-to-treat analysis was performed using last observation carried forward (LOCF).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Weight loss was 7.2% (SD = 5.2%) at 12 weeks and 12.3% (SD = 6.9%) at 24 weeks (<i>p</i> &lt; 0.0001). Mean BP declined from 131.0/83.8 (SD = 17.2/12.2) to 122.5/78.7 (SD = 13.7/10.1) at 12 weeks and 120.0/78.2 (SD = 13.5/10.6) at 24 weeks (<i>p</i> &lt; 0.0001). Participants significantly improved their eating habits, diet quality, and activity. Side effects were markedly lower than in previously reported trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Virtually delivered treatment combining telemedicine and a behavioral program tailored for long-acting AOMs demonstrated clinically significant improvements in weight, BP, diet, and activity over 24 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT06034457</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"18-28"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145552598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series","authors":"Michelle Wong,&nbsp;Ash Wu,&nbsp;Pawanjot K. Garhe,&nbsp;Mitch Biermann","doi":"10.1002/oby.70137","DOIUrl":"10.1002/oby.70137","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to evaluate whether reduced-frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective case series included 30 adults who achieved weight plateau while on weekly semaglutide or tirzepatide. Patients transitioned to reduced-frequency dosing (usually every other week) at their existing dose. Data were collected at three time points: pre-treatment, plateau (weekly dosing), and maintenance (reduced-frequency dosing). Primary outcome was change in body weight from plateau to maintenance. Secondary outcomes included body composition and metabolic syndrome comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients maintained reduced-frequency dosing for an average of 36.3 weeks. Weight decreased from 87.9 ± 2.4 kg at pre-treatment to 74.1 ± 2.4 kg at plateau and further to 72.4 ± 2.2 kg on maintenance dosing (<i>p</i> &lt; 0.01). Total body and truncal fat declined, while skeletal muscle mass stabilized on the reduced-frequency regimen. Metabolic parameters improved during weekly dosing and these gains were maintained during reduced-frequency therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes. These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"112-120"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70137","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity","authors":"Karan R. Chhabra,&nbsp;Nihan Gencerliler,&nbsp;Babak J. Orandi,&nbsp;Vivian Hsing-Chun Wang,&nbsp;Akio Kozato,&nbsp;Aditya Surapaneni,&nbsp;Morgan Grams,&nbsp;Amrita Mukhopadhyay,&nbsp;Jung-Im Shin,&nbsp;Christine Ren-Fielding,&nbsp;Manish Parikh,&nbsp;Donglan S. Zhang","doi":"10.1002/oby.70209","DOIUrl":"10.1002/oby.70209","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We compared health care spending and utilization associated with semaglutide relative to bariatric surgery in patients with obesity and type 2 diabetes (T2D).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, and major adverse cardiovascular events [MACE]). Analyses were adjusted using generalized linear models, inverse probability weighting, and instrumental variables.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 6748 patients (2797 semaglutide, 2300 sleeve gastrectomy, 1651 gastric bypass), bariatric surgery patients had higher BMI and more comorbidities. In IPTW-adjusted analysis, semaglutide was associated with the highest 3-year OOP costs ($7752 vs. $5980 [sleeve gastrectomy] vs. $6591 [gastric bypass], <i>p</i> &lt; 0.001), but total spending was not statistically different across the groups. Relative to semaglutide, the gastric bypass group showed higher observed ED visits (hazard ratio relative to semaglutide [95% CI]: 1.36 [1.28–1.45]) and inpatient admissions (1.25 [1.13–1.37]) and fewer MACE (0.71 [0.59–0.88]). Sleeve gastrectomy was associated with fewer long-term admissions (0.79 [0.72–0.86]) and MACE (0.79 [0.66–0.93]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>For patients with T2D and obesity, compared with semaglutide, bariatric surgery is associated with lower OOP spending and similar total spending at 3 years, as well as lower long-term MACE rates.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"65-76"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Effects of a Randomized Online Infant Sleep Intervention on Weight-Related Outcomes Into Toddlerhood","authors":"Stephanie Anzman-Frasca,&nbsp;Juliana Goldsmith,&nbsp;Amanda B. Hassinger,&nbsp;Gregory Wilding,&nbsp;Orfeu M. Buxton,&nbsp;Jennifer S. Savage","doi":"10.1002/oby.70037","DOIUrl":"10.1002/oby.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Behavioral sleep interventions may have lasting impacts on sleep and health and serve as a novel obesity prevention strategy. We explored effects of an online infant sleep intervention on sleep, weight status, and weight-related behaviors (e.g., diet) into toddlerhood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>First-time parents or legal guardians ≥ 18 years old were recruited when their infant was &lt; 6 weeks old and randomized (block size 2, 1:1 allocation ratio) to a sleep intervention (<i>n</i> = 36) or baby care control group (<i>n</i> = 38). The intervention was delivered weekly via private online groups when infants were 2–4 months old. Participants completed surveys at baseline (infant age 6 weeks), midpoint (3 months), post-intervention (4 months), and infant follow-up (7 months). Participants also completed a toddler follow-up survey (mean age = 20.7 months; <i>n</i> = 67) assessing behaviors and weight/length.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>By toddlerhood, the intervention group slept longer (12.99 ± 2.03 vs. 11.94 ± 2.06 h per day, <i>p</i> = 0.049) and had lower weight-for-length <i>z</i>-scores (0.62 ± 1.34 vs. 1.33 ± 1.35, <i>p</i> = 0.04) than controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Results support early sleep interventions as a novel and promising approach to childhood obesity prevention and demonstrate the feasibility of online intervention delivery. Future research should further examine mechanisms and confirm findings using objective weight status measures.</p>\u0000 \u0000 <p>\u0000 <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT05322174</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 S1","pages":"9-17"},"PeriodicalIF":4.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications","authors":"Kristina H. Lewis,&nbsp;Fang Zhang,&nbsp;Robert F. LeCates,&nbsp;Stephanie Argetsinger,&nbsp;Stefanie Albert,&nbsp;Geetha S. Iyer,&nbsp;John G. Connolly,&nbsp;James F. Wharam,&nbsp;David E. Arterburn,&nbsp;Dennis Ross-Degnan,&nbsp;Sengwee Toh","doi":"10.1002/oby.70208","DOIUrl":"10.1002/oby.70208","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Commercial insurance claims were used to identify new initiators of phentermine (<i>n</i> = 136,788), phentermine-topiramate-ER (<i>n</i> = 13,888), naltrexone-bupropion-SR (<i>n</i> = 28,712), or liraglutide (<i>n</i> = 49,266) for obesity. Multivariable difference-in-differences analyses compared the three newer drugs to phentermine for change in total annual prescription drug and health care costs, outpatient visits, and acute care use (combined emergency department visits and hospital stays).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Up to 3 years after OM initiation, prescription and total health care costs were higher for all three newer OM cohorts relative to phentermine, with liraglutide having the greatest comparative increase in annual costs (e.g., total costs 73.6% [70.9%, 76.3%] higher in year 1). Primary care physician visit frequency was slightly lower for the newer OMs (e.g., −12.6% [−13.6%, −11.6%] in year 1 for liraglutide).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The cost of OM treatment, even for medications that preceded highly effective weekly incretin analogues, appeared to increase overall prescription spending and total health care costs. Yet, other than a relative decrease in primary care physician visit frequency, more costly OMs were not associated with favorable changes in health care use patterns compared to generic phentermine. Reductions in OM cost and other interventions to support their longer-term use may be needed to fully realize the promise of these medications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 6","pages":"1331-1342"},"PeriodicalIF":4.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70208","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147936691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Preclinical and Clinical Obesity Among US Children and Adolescents Aged 5 to 18 Years: NHANES 2017–2023","authors":"Priyanka Chaudhary,&nbsp;Shengping Yang,&nbsp;Stephanie Waldrop,&nbsp;Peter T. Katzmarzyk,&nbsp;Amanda E. Staiano","doi":"10.1002/oby.70198","DOIUrl":"10.1002/oby.70198","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to estimate the prevalence of preclinical and clinical obesity among US youth using the Lancet Diabetes &amp; Endocrinology Commission's framework.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study examined NHANES 2017–2023 data from 5513 youth aged 5–18. Obesity classification included: (i) no obesity (BMI &lt; 95th percentile and/or waist to height ratio (WHtR) &lt; 0.5), (ii) preclinical obesity (BMI ≥ 95th percentile and WHtR ≥ 0.5 without clinical impairment or functional limitations), and (iii) clinical obesity (BMI ≥ 95th percentile and WHtR ≥ 0.5 with one or more clinical impairments or functional limitations).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The weighted prevalence was 8.3% for preclinical and 12.5% for clinical obesity; combined prevalence (20.8%) was similar to ~22% using BMI percentile alone. Clinical obesity was more common in older children and racial/ethnic minority groups but similar by sex. Impairments associated with clinical obesity included low HDL cholesterol (60.3%), asthma (24.8%), early menarche in girls (18.0%), elevated blood pressure (16.2%), prediabetes/diabetes (9.1%), and functional limitations related to walking (7.7%) and self-care (4.1%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Applying the Lancet Diabetes &amp; Endocrinology Commission's new definition criteria revealed substantial physiological dysfunction in US youth. Applying preclinical and clinical obesity definitions is challenging, given the limitations of the routinely collected clinical and epidemiological data that make up NHANES and in standard clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 6","pages":"1230-1236"},"PeriodicalIF":4.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147725327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stopping Spin at the Source: Learning From an Example in Obesity","authors":"Andrew W. Brown,&nbsp;Michael Jensen,&nbsp;David B. Allison","doi":"10.1002/oby.70159","DOIUrl":"10.1002/oby.70159","url":null,"abstract":"","PeriodicalId":215,"journal":{"name":"Obesity","volume":"34 6","pages":"1183-1186"},"PeriodicalIF":4.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}